Recurrent Islet Cell Carcinoma Withdrawn Phase 2 Trials for Dovitinib (DB05928)

IndicationStatusPhase
DBCOND0028802 (Recurrent Islet Cell Carcinoma)Withdrawn2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02108782Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine TumorsTreatment